In prostate cancer (PRAD) cells, the expression of CCR2 (the receptor of CCL2) promotes NI, and the expression of CCR2 is closely related to the activity of MAPK and Akt pathways and the migration of cancer cells to chemokine (C-C motif) ligand 2 (CCL2) and DRG [140]. The gene discussed is CCR2; the disease is prostate adenocarcinoma.